Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $4.9 million.

  • Xeris Biopharma Holdings' Cash from Investing Activities fell 100.72% to -$71,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 0.84%. This contributed to the annual value of $4.9 million for FY2024, which is 181.33% up from last year.
  • Xeris Biopharma Holdings' Cash from Investing Activities amounted to $4.9 million in FY2024, which was up 181.33% from -$6.0 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Cash from Investing Activities registered a high of $98.0 million during FY2021, and its lowest value of -$27.4 million during FY2020.
  • For the 3-year period, Xeris Biopharma Holdings' Cash from Investing Activities averaged around $11.1 million, with its median value being $4.9 million (2024).
  • Per our database at Business Quant, Xeris Biopharma Holdings' Cash from Investing Activities surged by 457.47% in 2021 and then crashed by 117.42% in 2023.
  • Xeris Biopharma Holdings' Cash from Investing Activities (Yearly) stood at -$27.4 million in 2020, then skyrocketed by 457.47% to $98.0 million in 2021, then plummeted by 64.82% to $34.5 million in 2022, then crashed by 117.42% to -$6.0 million in 2023, then surged by 181.33% to $4.9 million in 2024.